News | November 07, 2024
RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Subscribe To Our Newsletter & Stay Updated
